Antiphospholipid syndrome dilemmas still to be solved: 2008 Status

Annals of the Rheumatic Diseases

Volumn 67, Issue 4, 2008, Pages 438-442

  Shoenfeld, Yehuda ^a,d   Meroni, Pier Luigi ^b   Cervera, Ricard ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF MILAN   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; AUTOANTIBODY; CD20 ANTIBODY; CORTICOSTEROID DERIVATIVE; CYTOKINE RECEPTOR ANTAGONIST; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; EDITORIAL; HEALTH STATUS; HUMAN; INFECTION; INFLAMMATION; MEDICAL EDUCATION; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK ASSESSMENT; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; HUMANS;

EID: 41849121229     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.083873     Document Type: Editorial

References (54)

1. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 1983;287:1088-9.
2. Lockshin MD. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Di 2006;64:57-9.
3. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-7.
4. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;18:CD002859.
5. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
6. Kaul MS, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007 2007;66:927-30
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
8. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995;32:993-7.
9. Marai I, Zandman-Goddard G, Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 2004;33:365-72.
10. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006;65:2-6.
11. Pierangeli SS, Vega-Ostertag ME, Raschi E, Liu X, Romay-Penabad Z, De Micheli V, et al. Toll like receptor 4 is involved in antiphospholipid- mediated thrombosis: in vivo studies. Ann Rheum Dis 2007;66:1327-33.
12. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial I induction of autoantibodies to β2-glycoprotein-I accounts for the infectious aetiology of antiphospholipid syndrome. J Clin Invest 2002;109:797-804.
13. 2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome. Ann NY Acad Sci 2007;1108:481-8.
14. Sebastiani GD, Minisola G, Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev 2004;3:70-5.
15. Jiménez S, Tàssies D, Espinosa G, García-Criado A, Plaza J, Monteagudo J, et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/ IIIa increases arterial thrombosis and arterioesclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus Ann Rheum Dis Published Online First: 29 August 2007. doi:10.1136/ ard.2007.077321
16. Lopez-Pedrera C, Buendia P, Aguirre MA, Velasco F, Cuadrado MJ. Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus 2006;15:161-6.
17. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004;114:467-76.
18. Wolberg AS, Roubey RA. Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res 2004;114:391-6.
19. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008;77:51-6.
20. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005;106:2340-6.
21. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-4.
22. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167e1-5.
23. Cavazzana I, Nebuloni M, Cetin I, Acaia B, Saino S, Borghi MO, et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 2007;28:160-4.
24. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005;174:485-90.
25. Blank M, Krause I, Wildbaum G, Karin N, Shoenfeld Y. TNFa DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. Lupus 2003;12:546-9.
26. Martinez de la Torre Y, Buracchi C, Borroni EM, Dupor J, Bonecchi R, Nebuloni M, et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 2007;104:2319-24.
27. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007;109:422-30.
28. Sokol DK, O'Brien RS, Wagenknecht DR, Rao T, McIntyre JA. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol 2007;190:151-6.
29. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 2007;120:636-42.
30. Ziporen L, Shoenfeld Y, Levy Y, Korcyn AD, Neurological dysfunction and hyperactive behavior associated with antiphospholipid syndrome: a mouse model. J Clin Invest 1997;100:613-19.
31. Chapman J, Cohen-Armon M, Shoenfeld Y, Korcyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999;8:127-33.
32. Lavazza T, Dipinto A, Borghi MO, Usuelli V, Bergamaschi A, Zimarino V, et al. Antiphospholipid antibodies and central nervous system involvement: direct autoantibody binding to neuronal cells. Clin Exp Rheumatol 2007;25:25.
33. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006;54: 2505-14.
34. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003;62:1127.
35. Andreoli L, Pregnolato F, Burlingame R, Fanelli V, Allegri F, Radice A, et al. Antinucleosome antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 2007;25:35.
36. Shoenfeld Y, Ting G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 2008;30:74-83.
37. Stone S, Pijnenborg R, Vercruysse L, Poston R, Khamashta MA, Hunt BJ, Poston L. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006;27:457-67.
38. Erkan D, Harrison MJ, Levy B, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007;56:2382-91.
39. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999;96:5164-8.
40. Ostertag MV, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid- mediated thrombosis in mice. Lupus 2006;15:358-65.
41. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52:1545-54.
42. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004;114:467-76.
43. Yasuda S, Bohgaki M, Atsumi T, Koike T. Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiology 2005;210:775-80.
44. Shoenfeld Y, Gerli B, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-47.
45. Doria A, Sherer Y, Meroni PL, Shoenfeld Y. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 2005;31:355-62.
46. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004;112:169-74.
47. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Accelerated atheroma in the antiphospholipid syndrome. Rheum Dis Clin North Am 2006;32:537-51.
48. Jimenez S, Garcia-Criado MA, Tassies D, Reverter JC, Cervera R, Gilabert MR, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005;44:756-61.
49. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005;64:315-17.
50. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003;349:2407-15.
51. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
52. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;351:260-7.
53. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004;114:593-5.
54. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006;54:3918-25.